-+ 0.00%
-+ 0.00%
-+ 0.00%

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics An Exclusive Option To License PCS12852; Strengthens Balance Sheet With $7M Capital Infusion

Benzinga·07/01/2025 13:19:32
Listen to the news
  • Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852
  • Continue enrolling patients in Phase 2 study of PCS6422
  • Strengthened balance sheet with $7M capital infusion

     

VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.